Perspective on Nonsteroidal Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease

被引：1
|
作者：
Ghuman, Jasleen K. [1 ]
Tuttle, Katherine R. [1 ,2 ,3 ,4 ]
机构：
[1] Univ Washington, Div Nephrol, 1959 NE Pacific St,Box 356521, Seattle, WA 98195 USA
[2] Univ Washington, Kidney Res Inst, Sch Med, Div Nephrol, Seattle, WA USA
[3] Univ Washington, Inst Translat Hlth Sci, Sch Med, Seattle, WA USA
[4] Providence Med Res Ctr, Providence Hlth Care, Spokane, WA USA
来源：
KIDNEY360 | 2022年 / 3卷 / 04期
关键词：
diabetes and the kidney; chronic kidney disease prevention; diabetic kidney disease; kidney health; nonsteroidal mineralocorticoid receptor antagonist; FINERENONE; POTASSIUM;
D O I：
10.34067/KID.0007072021
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：744 / 748
页数：5
相关论文
共 50 条
  • [11] Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Vodosek Hojs, Nina
    Bevc, Sebastjan
    Ekart, Robert
    Piko, Nejc
    Petreski, Tadej
    Hojs, Radovan
    [J]. PHARMACEUTICALS, 2021, 14 (06)
  • [12] Mineralocorticoid Receptor Antagonism in Heart Failure and Chronic Kidney Disease
    Ferro, Charles J.
    Townend, Jonathan N.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (24) : 2437 - 2439
  • [13] Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
    Kovarik, Johannes J.
    Kaltenecker, Christopher C.
    Domenig, Oliver
    Antlanger, Marlies
    Poglitsch, Marko
    Kopecky, Chantal
    Saemann, Marcus D.
    [J]. DIABETES THERAPY, 2021, 12 (09) : 2485 - 2498
  • [14] Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
    Johannes J. Kovarik
    Christopher C. Kaltenecker
    Oliver Domenig
    Marlies Antlanger
    Marko Poglitsch
    Chantal Kopecky
    Marcus D. Säemann
    [J]. Diabetes Therapy, 2021, 12 : 2485 - 2498
  • [15] Role of Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
    Alexandrou, Maria-Eleni
    Theodorakopoulou, Marieta P.
    Sarafidis, Pantelis A.
    [J]. KIDNEY AND DIALYSIS, 2022, 2 (02): : 163 - 182
  • [16] Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
    Epstein, Murray
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (12): : 993 - 1003
  • [17] A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
    Fagart, Jerome
    Hillisch, Alexander
    Huyet, Jessica
    Baerfacker, Lars
    Fay, Michel
    Pleiss, Ulrich
    Pook, Elisabeth
    Schaefer, Stefan
    Rafestin-Oblin, Marie-Edith
    Kolkhof, Peter
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (39) : 29932 - 29940
  • [18] Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy
    Sato, Atsuhisa
    Nishimoto, Mitsuhiro
    [J]. HYPERTENSION RESEARCH, 2022, 45 (08) : 1310 - 1321
  • [19] Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy
    Atsuhisa Sato
    Mitsuhiro Nishimoto
    [J]. Hypertension Research, 2022, 45 : 1310 - 1321
  • [20] Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
    Bonnard, Benjamin
    Pieronne-Deperrois, Marie
    Djerada, Zoubir
    Elmoghrabi, Soumaya
    Kolkhof, Peter
    Ouvrard-Pascaud, Antoine
    Mulder, Paul
    Jaisser, Frederic
    Messaoudi, Smail
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2018, 121 : 124 - 133
12345